Generalized Anxiety Disorder Study for Those Who Have Had an Inadequate Response to Antidepressants
Official Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies
Purpose
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.
Could this study be right for you?
- Adults 18-65
- Diagnosed with GAD
- No depressive episodes in at least 6 months
- Currently receiving treatment of either paroxetine, escitalopram, duloxetine, or venlafaxine ER